TNX

What is the current level of analyst coverage and consensus on Tonix Pharmaceuticals, and are there any upcoming upgrades or downgrades linked to this filing?

Created August 11, 2025 at 08:39 PM

Analyst coverage & consensus

Tonix Pharmaceuticals (TNX) remains a thinly‑covered small‑cap biotech. At the time of the Q2 2025 release, only a handful of sell‑side analysts (roughly 3‑4) were publishing research on the stock, and the consensus view is modestly positive – the median “Buy” rating sits at about 70 % (≈ 2 Buys, 1 Neutral, 1 Sell). The “Consensus target price” is still in the early‑stage range of $1.30‑$1.45, reflecting the market’s optimism that the August 15 2025 PDUFA decision on TNX‑102 SL could be a catalyst.

Potential upgrades/downgrades

The filing itself does not trigger any scheduled rating changes. However, the upcoming PDUFA goal date (Aug 15 2025) is a key trigger point that analysts typically watch for. If the FDA grants approval, we can expect a near‑term upgrade from the existing “Buy”‑biased coverage as analysts move the target price higher and potentially raise their earnings forecasts. Conversely, a negative PDUFA outcome would likely prompt a downgrade or a shift to “Neutral/Reduce” ratings, given the drug’s central role in Tonix’s valuation. No formal upgrade or downgrade announcements have been disclosed yet, so the current consensus remains unchanged until the FDA decision.

Trading implication

With limited analyst coverage, price action is driven more by the PDUFA outcome than by incremental research upgrades. Until the August decision, the stock is best treated as a speculative, catalyst‑play: a modest long‑bias if you can tolerate volatility, but be prepared for a swift re‑rating swing once the FDA verdict is released. A breakout above $1.45 could attract fresh “Buy” coverage, while a breach below $1.20 may prompt the first downgrades.

Other Questions About This News

What are the potential upside and downside scenarios if the FDA approves or rejects TNX‑102 SL, and how should position sizing be adjusted accordingly? What historical price reaction has Tonix experienced around similar FDA decision milestones, and can that inform expected volatility? How will the earnings results and operational highlights reported for Q2 2025 influence the broader market narrative around Tonix’s growth trajectory? How will the FDA PDUFA goal date of August 15, 2025 for TNX‑102 SL affect the stock’s short‑term price movement? What is the market’s perception of TNX‑102 SL being the first new fibromyalgia drug in over 16 years, and how might that influence demand and valuation? How does the projected revenue and profit potential of TNX‑102 SL compare to existing fibromyalgia treatments and other pipeline candidates at Tonix? How might the approval timeline impact the company’s cash runway and need for additional financing or dilution? What competitive threats exist from other companies developing fibromyalgia therapies, and how could they affect market share if TNX‑102 SL is approved? Are there any contingent milestones or partnership agreements tied to the approval of TNX‑102 SL that could further move the stock?